Myotoxicity studies of O/W-in situ forming microparticle systems

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 69, Issue 1, 2008, Pages 126-133

  Rungseevijitprapa, Wandee ^a   Brazeau, Gayle A ^b   Simkins, James W ^b   Bodmeier, Roland ^c  

^a UBON RATCHATHANI UNIVERSITY   (Thailand)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

^c FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Creatine kinase; In situ forming; Microparticles; Myotoxicity; Solvents

Indexed keywords

ACETIC ACID ETHYL ESTER; BENZYL ALCOHOL; CITRIC ACID TRIETHYL ESTER; CREATINE KINASE; PHENYTOIN; POLOXAMER; POLYMER; PROPYLENE CARBONATE; SODIUM CHLORIDE; SOLVENT; TRIACETIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; EMULSION; IN SITU FORMING MICROPARTICLE SYSTEM; IN VITRO STUDY; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; MUSCLE INJURY; MUSCLE TOXICITY; NONHUMAN; RAT; SKELETAL MUSCLE; SPRAGUE DAWLEY RAT; TOXICITY;

ACETATES; ANIMALS; CHEMISTRY, PHARMACEUTICAL; CREATINE KINASE; MALE; MICROSPHERES; MUSCLES; PHENYTOIN; POLYMERS; RATS; RATS, SPRAGUE-DAWLEY; SODIUM CHLORIDE; SOLVENTS; TECHNOLOGY, PHARMACEUTICAL; VISCOSITY;

EID: 41549110163     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2007.10.009     Document Type: Article

References (46)

1. Dong W.Y., Körber M., Esguerra V.L., and Bodmeier R. Stability of poly(d,l-Lactide-co-glycolide) and leuprolide acetate in in-situ forming drug delivery systems. J. Control. Release 115 (2006) 158-167
2. Luan X., and Bodmeier R. Influence of the poly(lactide-co-glycolide) type on the leuprolide release from in situ forming microparticle systems. J. Control. Release 110 (2006) 266-272
3. Hatefi A., and Amsden B. Review: biodegradable injectable in situ forming drug delivery systems. J. Control. Release 80 (2002) 9-28
4. Cleland J.L. Injectable gels for local and systemic delivery of proteins. Proc. Int. Symp. Contr. Rel. Bioact. Mater. (2001) 45-46
5. ®DepotTM. Proc. Int. Symp. Contr. Rel. Bioact. Mater. (2001) 692-693
6. Duenas E., Okumu F., Daugherty A., and Cleland J. Sustained delivery of rhVEGF from a novel injectable liquid. PLAD. Proc. Int. Symp. Contr. Rel. Bioact. Mater. (2001) 1041-1042
7. Hussain M.D., and Dunn R.L. Controlled release of ciprofloxacin HCL from injectable biodegradable polymeric implants for post-surgical. Proc. Int. Symp. Contr. Rel. Bioact. Mater. (2001) 133-134
8. Okumu F.W., Daugherty A., Dao L., Fielder P.J., Brooks D., Sane S., and Cleland J.L. Sustained delivery of growth hormone from a novel injectable liquid. PLAD. Proc. Int. Symp. Contr. Rel. Bioact. Mater. (2001) 1029-1030
9. Rackur H. In-situ forming implants of PLGA/leuprolide acetate solutions in NMP and their in vitro/in vivo release characteristics. Proc. Int. Symp. Contr. Rel. Bioact. Mater. (2001) 884-885
10. Lambert W.J., and Kendall D.P. Development of an in situ forming biodegradable poly-lactide-co-glycolide system for the controlled release of proteins. J. Control. Release 33 (1995) 185-195
11. Dunn R.L., Tipton A.J., and Menardi E.M. A biodegradable in-situ forming drug delivery system. Proc. Int. Symp. Contr. Rel. Bio. Mater. (1991) 465
12. Tipton A.J., Fujita S.M., Frank K.R., and Dunn R.L. Release of naproxen from a biodegradable, injectable delivery system. Proc. Int. Symp. Contr. Rel. Bioact. Mater. 19 (1992) 314-315
13. Shah N.H., Railkar A.S., Chen F.C., Tarantino R., Kumar S., Murjani M., Plamer D., Infeld M.H., and Malick A.W. A biodegradable injectable implant for delivering micro and macromolecules using poly(lactic-co-gylcolic) acid (PLGA) copolymer. J. Control. Release 27 (1993) 139-147
14. Lambet W.J., and Peck K.D. An in situ forming biodegradable system for controlled release of proteins. Pharm. Res. 10 (1993) S-192
15. Ravivarapu H.B., Moyer K.L., and Dunn R.L. Parameter affecting the efficacy of a sustained release polymeric implant of leuprolide. Int. J. Pharm. 194 (2000) 181-191
16. Ravivarapu H.B., Moyer K.L., and Dunn R.L. Sustained suppression of pituitary-gonadal axis with an injectable, in situ forming implant of leuprolide acetate. J. Pharm. Sci. 89 6 (2000) 732-741
17. Radomsky M.L., Brower G., Floy B.J., Loury D.J., Chu F., Tipton A.J., and Sanders L.M. The controlled release of gainirelix from the Atrigel injectable implant system. Proc. Int. Symp. Contr. Rel. Bio. Mater. 20 (1993) 458
18. Coonts B.A., Lowe B.K., Norton R.L., Tipton A.J., Yewey G.L., and Dunn R.L. Plasma concentrations of naltrexone following subcutaneous and intramuscular injections of Atrigel formulations in dogs. Pharm. Res. 10 (1996) S-92
19. Shah N.H., Railkar A.S., Chen F.C., Tarantino R., Kumar S., Murjani M., Plamer D., Infeld M.H., and Malick A.W. A biodegradable injectable implant for delivering micro and macromolecules using poly(lactic-co-glycolic) acid (PLGA) copolymer. J. Control. Release 27 (1993) 139-147
20. Duysen E.G., Yewey G.L., Southard J.L., Dunn R.L., and Huffer W. Release of bioactive growth factors from the Atrigel delivery system in tibial defect and dermal wound models. Pharm. Res. 10 (1993) S-83
21. Tipton A.J., Fujita S.M., Frank K.R., and Dunn R.L. A biodegradable injectable delivery system for non-steroidal anti-inflammatory drugs. Pharm. Res. 8 (1991) S-196
22. Jain R.A., Rhod C.T., Railkar A.M., Malick A.W., and Shah N.H. Controlled delivery of drug from a novel injectable in situ formed biodegradable PLGA microsphere system. J. Microencap. 17 3 (2000) 343-362
23. H. Kranz, G.A. Brazeau, R. Bodmeier, A novel in situ forming drug delivery system (ISM) for controlled parenteral drug delivery. Proc. 3rd World Meeting APV/APGI, Berlin, 2000, 363-364.
24. W. Im-Emsap, R. Bodmeier, O/W in situ forming microparticle (ISM) systems: effect of phase ratio on emulsion viscosity, injectability, microparticle size and drug release. Proc. 4th World Meeting APV/APGI, Florence, Italy, 2002, 1501, 4-6 April.
25. R. Bodmeier, Multiphase system. Int. Patent Application WO 98/55100, 1998.
26. R. Bodmeier, Polymer-based sustained release particle dispersions. Int. Patent Application WO 02/19988, 2002.
27. Im-Emsap W., Paeratakul O., and Siepmann J. Disperse systems. In: Banker G.S., and Rhodes C.T. (Eds). Modern Pharmaceutics (Revised and Expanded) fourth ed. (2002), Marcel Dekker, New York 237-285
28. W. Im-Emsap, R. Bodmeier, In vitro drug release from in situ forming microparticle (ISM)-systems with dispersed drug. in: 15th Meeting of the American Association of Pharmaceutical Scientists AAPS, Indianapolis, USA, 2000.
29. W. Im-Emsap, G.A. Brazeau, J.W. Simpkins, R. Bodmeier, Sustained drug delivery of 17-β estradiol from injectable biodegradable in situ forming microparticles (ISM) system. in: 15th Meeting of the American Association of Pharmaceutical Scientists AAPS, Indianapolis, USA, 2000.
30. Kranz H., Brazeau G.A., Napaporn J., Martin R.L., Milard W., and Bodmeier R. Myotoxicity studies of injectable biodegradable in-situ forming drug delivery systems. Int. J. Pharm. 212 (2001) 11-18
31. ® Implant Drug Delivery Technology for Patient-Friendly, Cost-Effective Product Development http://www.drugdeliverytech.com/cgi-bin/articles.cgi?idArticle=161.
32. Quintanar-Guerrero D., Fessi H., Allémann E., and Doelker E. Influence of stabilizing agents and preparative variables on the formation of poly(d,l-lactic acid) nanoparticles by an emulsification-diffusion technique. Int. J. Pharm. 143 (1996) 133-141
33. Sznitowska M., Gajewska M., Janicki S., Radwanska A., and Lukowski G. Bioavailability of diazepam from aqueous-organic solution, submicron emulsion and solid lipid nanoparticles after rectal administration in rabbits. Eur. J. Pharm. Biopharm. 52 2 (2001) 159-163
34. Dong W.Y., Körber M., López Esguerraand V., and Bodmeier R. Stability of poly(d,l-lactide-co-glycolide) and leuprolide acetate in in-situ forming drug delivery systems 115 2 (2006) 158-167
35. Thurman R.G., and Kauffman F.C. Benzyl alcohol. Ethel Browning's Toxicity and Metabolism of Industrial Solvents. Volume III: Alcohols and Esters. second ed. (1992), Elsevier, New York 215-223
36. Thurman R.G., and Kauffman F.C. Ethyl acetate. Ethel Browning's Toxicity and Metabolism of Industrial Solvents. Volume III: Alcohols and Esters. second ed. (1992), Elsevier, New York 233-246
37. Meyer D.B., Aulian J., and Guess W.L. Toxicity of plastics used in medical practice II: toxicity of citric acid esters used as plasticizers. J. Pharm. Sci. 53 (1964) 774-777
38. Brazeau G.A., and Fung H.L. Use of an in-vitro model to evaluate muscle damage following intramuscular injections. Pharm. Res. 6 (1989) 167-179
39. Brazeau G.A., and Fung H.L. Use of an in-vitro model for the assessment of muscle damage from intramuscular injection: in-vitro-in-vivo correlation and predictability with mixed solvent systems. Pharm. Res. 6 (1989) 766-771
40. Brazeau G.A., and Fung H.L. Mechanism of creatine kinase release from isolated rat skeletal muscles damaged by propylene glycol and ethanol. J. Pharm. Sci. 79 (1990) 393-397
41. Brazeau G.A., Sciame M., Al-Suwayeh S.A., and Fattal E. Evaluation of PLGA microspheres size effect on myotoxicity using the isolated rodent skeletal muscle model. Pharm. Dev. Technol. 1 (1996) 279-283
42. Al-Suwayeh S.A., Tebbett I.R., Wielbo D., and Brazeau G.A. In vitro-In vivo myotoxicity of intramuscular liposomal formulations. Pharm. Res. 13 9 (1996) 1384-1388
43. Oliver I.T. A spectrophotometric method for the determination of creatine kinase. J. Lab. Clin. Med. 62 (1963) 159
44. Szasz G., Gerhardt W., and Gruber W. Creatine kinase in serum. 5. Effects of thiols on isozyme activity during storage at various temperatures. Clin. Chem. 24 (1978) 1557-1565
45. Sah H. Microencapsulation techniques using ethyl acetate as a dispersed solvent: effects of its extraction rate on the characteristics of PLGA microspheres. J. Control. Release. 47 (1997) 233-245
46. Spiegel A.J., and Noseworthy M.M. Use of nonaqueous solvents in parenteral products. J. Pharm. Sci. 52 10 (1963) 917-927